This invention discloses the application of
ornithine aspartate in the preparation of drugs for treating systemic aging. By applying
ornithine aspartate to regulate the systemic aging process, this invention can effectively improve
hepatocyte dysfunction, restore
cell proliferation activity, alleviate
cell cycle arrest, and reduce the
abnormal expression of aging-related genes and proteins in multiple tissues and organs such as the liver, kidneys, heart, muscles, and fat, thereby delaying the aging process. This technical solution can significantly improve the structural disorder and
lipid deposition in aging
liver tissue, reduce
serum transaminase levels, improve
liver function, reduce
insulin resistance, inhibit the overexpression of SASP-related
inflammatory factors, and maintain metabolic
homeostasis. Furthermore, it effectively improves aging phenotypes in multiple tissues and organs. Therefore, this invention has significant technical effects and application potential in delaying systemic aging and improving
motor function and metabolic abnormalities.